Porphyrins containing nitric oxide donors: Synthesis and cancer cell-oriented NO release

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 6, 2009, Pages 1647-1649

  Liu, Wukun ^a   Liu, Chaozhou ^a   Gong, Changjun ^a   Lin, Weiying ^a   Guo, Cancheng ^a  

^a HUNAN UNIVERSITY   (China)

Author keywords

Biological evaluation; Nitric oxide donors; Porphyrin; Synthesis

Indexed keywords

CYSTEINE; FLUOROURACIL; MESO 5 (2' NITROOXYETHOXYPHENYL) 10,15,20 TRI(METHYLPHENYL)PORPHYRIN; MESO 5 (2' NITROOXYPHENYL) 10,15,20 TRIPHENYLPORPHINE; MESO 5 (3' NITROOXYPROPOXYPHENYL) 10,15,20 TRI(METHYLPHENYL)PORPHYRIN; MESO 5 (3' NITROOXYPROPOXYPHENYL) 10,15,20 TRIPHENYLPORPHINE; NITRIC OXIDE; NITRIC OXIDE DONOR; PORPHYRIN DERIVATIVE; TETRAPHENYLPORPHYRIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; INFRARED RADIATION; LIVER CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; ULTRAVIOLET SPECTROSCOPY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE DONORS; PORPHYRINS; SPECTROPHOTOMETRY, INFRARED; SPECTROPHOTOMETRY, ULTRAVIOLET; TETRAZOLIUM SALTS; THIAZOLES;

EID: 61349144433     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.02.005     Document Type: Article

References (31)

1. Lundberg J.O., Weitzberg E., and Gladwin M.T. Nat. Rev. Drug Discov. 7 (2008) 156
2. Grisham M.B., Jourd'Heuil D., and Wink D.A. Am. J. Physiol. 276 (1999) G315
3. Hou Y.C., Janczuk A., and Wang P.G. Curr. Pharm. Des. 5 (1999) 417
4. Wang P.G., Xian M., Tang X., Wu X., Wen Z., Cai T., and Janczuk A.J. Chem. Rev. 102 (2002) 1091
5. Ekmekcioglu S., Tang C.H., and Grimm E.A. Curr. Cancer Drug Targets 5 (2005) 103
6. Kerwin J.J., and Heller M. Med. Res. Rev. 14 (1994) 23
7. Jia Q., Janczuk A.J., Cai T., Xian M., Wen Z., and Wang P.G. Exp. Opin. Ther. Pat. 12 (2002) 819
8. Cai T.B., and Wang P.G. Ther. Pat. 12 (2004) 849
9. Hirst D., and Robson T. J. Pharm. Pharmacol. 59 (2007) 3
10. Sullivan R., and Graham C.H. Curr. Pharm. Des. 14 (2008) 1113
11. Praneeth V.K., Näther C., Peters G., and Lehnert N. Inorg. Chem. 45 (2006) 2795
12. Praneeth V.K., Neese F., and Lehnert N. Inorg. Chem. 44 (2005) 2570
13. Lehnert N., Praneeth V.K., and Paulat F. J. Comput. Chem. 27 (2006) 1338
14. Winkelman J., Slater G., and Grossman J. Cancer Res. 27 (1967) 2060
15. Tronconi M., Colombo A., De Cesare M., Marchesini R., Woodburn K.W., Reiss J.A., Phillips D.R., and Zunino F. Cancer Lett. 88 (1995) 41
16. Detty M.R., Gibson S.L., and Wagner S.J. J. Med. Chem. 47 (2004) 3897
17. Dolmans D.E., Fukumura D., and Jain R.K. Nat. Rev. Cancer 3 (2003) 380
18. Zheng X., and Pandey R.K. Anticancer Agents Med. Chem. 8 (2008) 241
19. Fukumura D., Kashiwagi S., and Jain R.K. Nat. Rev. Cancer 6 (2006) 521
20. Guo C.C., Li H.P., and Zhang X.B. Bioorg. Med. Chem. 11 (2003) 1745
21. Guo C.C., Tong R.B., and Li K.L. Bioorg. Med. Chem. 12 (2004) 2469
22. Cai Z.F., Feng J., Guo Y.S., Li P.P., Shen Z.F., Chu F.M., and Guo Z.R. Bioorg. Med. Chem. 14 (2006) 866
23. 5: C, 53.33; H, 4.92; N, 6.22; O, 35.53. Found: C, 53.53; H, 4.72; N, 6.05; O, 37.50.
24. Adler A.D., Longo F.R., Finarelli J.D., Goldmacher J., Assour J., and Korsakoff L. J. Org. Chem. 32 (1967) 476
25. Lindsey J.S., Schreiman I.C., Hsu H.C., Kearney P.C., and Marguerettaz A.M. J. Org. Chem. 52 (1987) 827
26. 2: 419, 481, 517.5, 552, 647.
27. In vitro nitric oxide release assays. (1) Incubation with 18 mM l-cysteine in phosphate buffer (pH 7.4). A solution of the test compound (1 mL of a 0.2 mM solution in 0.1 M phosphate buffer, pH 7.4) was mixed thoroughly with a freshly prepared solution of l-cysteine (1 mL of a 3.6 mM solution in 0.1 M phosphate buffer, pH 7.4), and the mixture was incubated at 37 °C for 1.5 h in the absence of air. After exposure to air for 10 min at 25 °C, an aliquot of the Griess reagent (1 mL) (freshly prepared by mixing equal volumes of 1.0% sulfanilamide and 0.1% N-naphthylethylenediamine dihydrochloride in water) was added to an equal volume (1 mL) of each test compound's incubation solution with mixing. After 10 min had elapsed, absorbance was measured at 540 nm using a Simadzu UV 2100 UV-vis scanning spectrophotometer. Solutions of 0-100 μM sodium nitrite were used to prepare a nitrite absorbance versus concentration curve under the same experimental conditions. The percent nitric oxide released (quantitated as nitrite ion) was calculated (±SEM, n = 3) from the standard nitrite versus concentration curve. (2) Incubation with phosphate buffer (pH 7.4). This assay was performed as described under procedure 1 above except that a solution of the test compound (2 mL of a 2 mM solution in 0.1 M phosphate buffer pH 7.4) was used and no l-cysteine was added.
28. Civelli M., Caruso P., Giossi M., Bergamaschi M., Razzetti R., Bongrani S., and Gasco A. Br. J. Pharmacol. 118 (1996) 923
29. Carystinos G.D., Alaoui-Jamali M.A., and Batist G. Cancer Chemother. Pharmacol. 47 (2001) 126
30. 50) was determined for the various compounds tested.
31. 2 atmosphere, the drug-containing medium was removed and their absorbance was measured using a Simadzu UV 2100 UV-vis scanning spectrophotometer.